Araştırma Makalesi

Histone deacetylase inhibitory and antioxidant activities of some ethanolic plant extracts: A novel therapeutic approach for cancer

Cilt: 48 Sayı: 3 30 Eylül 2023
PDF İndir
TR EN

Histone deacetylase inhibitory and antioxidant activities of some ethanolic plant extracts: A novel therapeutic approach for cancer

Abstract

Purpose: The aim of this study was to evaluate histone deacetylase inhibitory and antioxidant activities of some ethanolic plant extracts. Materials and Methods: In this study, the inhibitory effects of ethyl alcohol extracts prepared from various plants and some chemical compounds on histone deacetylase activity were investigated. In addition, the antioxidant activity of plant-derived active substances, which have had an important value in alternative medicine in recent years, has been determined to replace chemicals. Results: All the plant extracts and chemical substances used in the study showed histone deacetylase inhibitory effect (with IC50 range of 0.000078-319.0 µg/mL) and antioxidant activity. The results indicated that the percentage of histone deacetylase inhibition and antioxidant activities increased with increasing concentrations of the plant extracts and chemical compounds. Conclusion: These plant extracts which are potential sources of histone deacetylase inhibitors may be appropriately used as an alternative support to drug treatment rather than the use of toxic chemicals.

Keywords

Antioxidant activity , cancer , enzyme inhibition , histone deacetylase , plant extract.

Kaynakça

  1. Yang S, Huang Y, Zhao Q. Epigenetic alterations and inflammation as emerging use for the advancement of treatment in non-small cell lung cancer. Front Immunol. 2022;13:878740.
  2. Huynh NCN, Everts V, Ampornaramveth RS. Histone deacetylases and their roles in mineralized tissue regeneration. Bone Rep. 2017;7:33–40.
  3. Kalin JH, Wu M, Gomez AV, Song Y, Das J, Hayward D et al. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun. 2018;9:53.
  4. Chen D, Shen A, Fang G, Liu H, Zhang M, Tang S et al. Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer. Acta Pharm Sin B. 2016;6:93–9.
  5. Cerna T, Hrabeta J, Eckschlager T, Frei E, Schmeiser H, Arlt V et al. The histone deacetylase inhibitor valproic acid exerts a synergistic cytotoxicity with the DNA-damaging drug ellipticine in neuroblastoma cells. Int J Mol Sci. 2018;19:164.
  6. Wang Y, Abrol R, Mak JYW, Das Gupta K, Ramnath D, Karunakaran D et al. Histone deacetylase 7: A signalling hub controlling development, inflammation, metabolism and disease. FEBS J. 2023;290:2805-32.
  7. Chittur SV, Sangster-Guity N, McCormick PJ. Histone deacetylase inhibitors: A new mode for inhibition of cholesterol metabolism. BMC Genomics. 2008;9:507.
  8. Mottamal M, Zheng S, Huang T, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015;20:3898–941.
  9. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett. 2009;277:8–21.
  10. Cai MH, Xu XG, Yan SL, Sun Z, Ying Y, Wang BK et al. Depletion of HDAC1, 7 and 8 by histone deacetylase inhibition confers elimination of pancreatic cancer stem cells in combination with gemcitabine. Sci Rep. 2018;8:1621.

Kaynak Göster

MLA
Dağsuyu, Eda, ve Refiye Yanardağ. “Histone deacetylase inhibitory and antioxidant activities of some ethanolic plant extracts: A novel therapeutic approach for cancer”. Cukurova Medical Journal, c. 48, sy 3, Eylül 2023, ss. 888-01, doi:10.17826/cumj.1316664.